Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–31 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
Interventions
MEDI0457, Durvalumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment
Drug · Radiation · Other + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions
Gabapentin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Interventions
Cisplatin, Radiation therapy, Vorinostat
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Robotic surgery
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Paramus, New Jersey • New York, New York
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
FMISO-PET Scan, Chemoradiation, Assessments
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more